

1 **The association of neutralizing antibodies with protection against**
2 **symptomatic dengue virus infection varies by serotype, prior infection**
3 **history, and assay condition**

4
5 Sandra Bos^{1,#*}, Aaron L. Graber^{1,#}, Jaime A. Cardona-Ospina¹, Elias M. Duarte¹, Jose Victor
6 Zambrana^{2,3}, Jorge A. Ruíz Salinas², Reinaldo Mercado-Hernandez¹, Tulika Singh¹, Leah C.
7 Katzelnick⁴, Aravinda de Silva⁵, Guillermina Kuan^{2,6}, Angel Balmaseda^{2,7}, Eva Harris^{1*}

8
9 # These authors contributed equally

10 *Co-corresponding authors

11
12 ¹Division of Infectious Diseases and Vaccinology, School of Public Health, University of California,
13 Berkeley, Berkeley, CA, USA

14 ²Sustainable Sciences Institute, Managua, Nicaragua

15 ³Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI,
16 USA

17 ⁴Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of
18 Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

19 ⁵Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA

20 ⁶Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua

21 ⁷Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de
22 Salud, Managua, Nicaragua

23 **Abstract**

24 The four dengue virus serotypes (DENV1–4) are the most prevalent arboviruses in humans and
25 a major public health concern worldwide. Understanding immune mechanisms that modulate
26 DENV infection outcome is critical for epidemic preparedness and development of a safe and
27 effective vaccine. Neutralizing antibodies (nAbs) are an essential component of the protective
28 response, yet their measurement often relies on a single cellular substrate and partially mature
29 virions, which do not capture the full breadth of neutralizing activity and may lead to biased
30 estimations of nAb potency. Here, we investigated the characteristics of nAbs associated with
31 protection against dengue cases using samples collected after one or more DENV infections but
32 prior to subsequent symptomatic or inapparent DENV1, DENV2, or DENV3 infections from a long-
33 standing pediatric cohort study in Nicaragua. By assessing nAb responses using Vero cells with
34 or without the attachment factor DC-SIGN and with mature or partially mature virions, we found
35 that nAb potency and the protective NT₅₀ cutoff were greatly influenced by cell substrate and virion
36 maturation state. Additionally, the correlation between nAb titer and protection from disease
37 depended on an individual's prior infection history and the subsequent infecting DENV serotype.
38 Finally, we uncovered variations in nAbs composition that contributed to protection from
39 symptomatic DENV infection differently after primary and secondary prior infection. These
40 findings have important implications for identifying antibody correlates of protection in the context
41 of vaccines and natural infections.

42 **Introduction**

43 The four dengue virus serotypes (DENV1-4) are mosquito-borne flaviviruses endemic to
44 tropical and subtropical regions that cause the most prevalent arthropod-borne viral disease in
45 humans. Up to 100 million people are infected each year, of whom approximately 50 million
46 develop symptoms ranging from self-limiting but debilitating dengue fever to potentially fatal
47 dengue shock syndrome¹. Infection with one of the four antigenically related DENV serotypes
48 leads to the production of type-specific antibodies, which are specific to the infecting serotype, as
49 well as cross-reactive antibodies that can bind to other DENV serotypes. These cross-reactive
50 antibodies can either provide protection or increase the risk of subsequent symptomatic or severe
51 DENV infection after both natural infections and vaccines²⁻⁶. The occurrence of such adverse
52 events emphasizes the complexity of DENV immunity and the crucial need for a comprehensive
53 evaluation of correlates of protection to facilitate studies of natural infections and the development
54 of safe and effective DENV vaccines.

55 Neutralizing antibodies (nAbs) are essential for protection against dengue in both natural
56 infections and vaccine trials^{5,7}. The composition and magnitude of pre-existing nAbs can vary
57 depending on the previous infecting serotype and number of previous infections²⁻⁵. The current
58 "gold standard" to assess the neutralizing potential of nAbs are Plaque or Focus Reduction
59 Neutralization Tests (PRNT/FRNT), where serum/plasma samples are serially diluted to measure
60 viral infectivity⁸. Vaccine trials to evaluate correlates of protection usually perform DENV
61 neutralization assays according to the reference assay conditions with Vero cells as substrate
62 and WHO reference DENV strains grown in either mammalian (Vero) or insect (C6/36) cells⁸.
63 Although higher nAb titers correlate with a reduced risk of dengue disease, symptomatic dengue
64 cases can occur in individuals with relatively high nAb titers, suggesting that the current
65 neutralization assays may not adequately measure the types of nAbs critical for protection^{5,7}.

66 The DENV genome encodes three structural proteins -- envelope (E), precursor
67 membrane/membrane (prM/M), and capsid (C) -- that form the virion and seven nonstructural
68 proteins responsible for viral replication, assembly, and immune evasion⁹. Neutralizing antibodies

69 primarily target the envelope (E) protein of the virus, and nAb potency is influenced by the epitope
70 they target. The epitope itself determines the required amount of antibodies to neutralize a viral
71 particle (stoichiometry), and their efficiency varies depending on viral strain and physiological
72 environment. Thus, several factors, including the temperature of incubation, the maturation state
73 of the virion, the viral strain, and the choice of cell substrate impact the type of antibody measured.
74 As a result, neutralization assay conditions can modulate nAb potency^{10,11} and the ability to
75 measure antibody “repertoire” composition and functionality, referred to here as “quality”.

76 DENV FRNT/PRNTs are commonly performed using DENV laboratory strains grown in
77 Vero cells, which may not reflect the maturation state of virus circulating in human subjects¹⁰.
78 During viral assembly, immature particles are formed in the endoplasmic reticulum and
79 transported to the extracellular surface through the Golgi network, where they undergo
80 maturation. These immature particles are characterized by a spiky surface formed by trimeric
81 prM-E heterodimers, with pr peptides capping the E fusion loop (FL)¹². Their transit through the
82 acidic compartment of the Golgi network results in a rearrangement of the E proteins (trimers to
83 dimers), and maturation occurs by cleavage of prM by the host protease furin^{13,14}. Upon release
84 into the neutral pH of the extracellular medium, the pr peptides detach, revealing the smooth
85 mature viral progeny that are infectious. However, maturation is not always complete. Areas
86 where pr has not been cleaved revert to trimeric spikes once virions are secreted, creating mosaic
87 particles harboring different organizations of E proteins on their surface¹⁵. This difference in
88 maturation state changes the proportion and identity of epitopes exposed and, thus, the number
89 and type of antibodies required to completely neutralize infectious viral particles^{11,16}.

90 In addition, the cellular substrate of the neutralization assay is an important factor that can
91 influence neutralization potency, as it determines the host receptors relevant for viral entry. Unlike
92 other flaviviruses, the E protein of DENV has an additional glycosylation site at Asp-67 (E domain
93 I), which allows DENV to enter cells through interaction with the DC-SIGN attachment factor¹⁷.
94 DC-SIGN is expressed on dendritic cells (DCs) and monocytes, which account for the majority of
95 DENV-infected cells in the blood^{18–23}. DCs are potent antigen-presenting cells that mediate both
96 innate and adaptive immunity by producing cytokines and transporting antigens to secondary

97 lymphoid organs, where they prime naïve antigen-specific T cells. Nevertheless, *in vitro* studies
98 have shown that while DENV2-infected DCs can undergo activation and release of pro-
99 inflammatory cytokines, they do not secrete IFN- α/β , which is critical for T cell priming²⁰.
100 Meanwhile, monocytes facilitate viral dissemination to various peripheral organs by acting as
101 Trojan horses and transporting DENV virions to target tissues²⁴. DC-SIGN promoter
102 polymorphism in humans contributes to genetic susceptibility to DENV infection and is a risk factor
103 for developing severe dengue disease. As a result, efficient neutralization in the presence of DC-
104 SIGN is important for limiting viral dissemination and for the establishment of a rapid and effective
105 cell-mediated immune response²⁰. Evaluation of DC-SIGN-mediated entry in an FRNT/PRNT
106 assay enables a broad assessment of neutralizing potential of nAbs by measuring the impact of
107 nAbs that prevent N-glycan interaction and should be considered when investigating immune
108 correlates of protection.

109 Here, we used a set of plasma samples from our long-standing prospective pediatric
110 dengue cohort study in Nicaragua and evaluated the cross-reactive nAb response prior to
111 subsequent inapparent or symptomatic infections with DENV1, DENV2, or DENV3. We compared
112 neutralization potency across multiple assay conditions using partially mature and mature virions
113 on Vero cells and Vero cells expressing DC-SIGN. Using these four assay conditions, we
114 evaluated the nAb magnitude and quality associated with protection against symptomatic DENV
115 infection. We found that correlation with protection is dependent on the individual's prior DENV
116 infection history and the subsequent infecting serotype, as well as assay conditions. Further, we
117 show that comparison of nAb titers obtained with partially mature versus mature virions and
118 presence or absence of DC-SIGN can indicate the characteristics of antibodies that are important
119 for protection.

120 **Materials and Methods**

121 **Ethics statement**

122 The human subjects protocol for the Pediatric Dengue Cohort Study (PDCS) was reviewed and
123 approved by the Institutional Review Boards (IRB) of the University of California, Berkeley (2010-

124 09-2245), the University of Michigan (HUM00091606), and the Nicaraguan Ministry of Health
125 (CIRE-09/03/07-008). Parents or legal guardians of all subjects provided written informed
126 consent, and subjects 6 years of age and older provided assent.

127 **Samples and study population**

128 The PDCS is an ongoing open prospective cohort of 4,000 children 2-17 years old that was
129 initiated in 2004^{6,25}. Blood samples are collected annually, and additional samples are collected
130 from symptomatic suspected dengue cases at the acute (0-6 days post-onset of symptoms) and
131 convalescent (14-21 days post-onset of symptoms) phase. DENV infections are evaluated and
132 recorded yearly by comparing healthy annual serum/plasma samples collected in two consecutive
133 years side-by-side by inhibition enzyme-linked immunosorbent assay (iELISA)². A ≥ 4 -fold
134 increase in iELISA titer between annual samples is considered as indication of an infection²⁶.

135 Symptomatic dengue cases were confirmed by detection of DENV RNA by RT-PCR, real-
136 time RT-PCR and/or virus isolation in the acute-phase sample; seroconversion of DENV-specific
137 immunoglobulin M antibodies in paired acute- and convalescent-phase samples; or a ≥ 4 -fold
138 increase in antibody titer by iELISA between acute and convalescent sera^{2,27-29}. The serotype of
139 symptomatic infections was determined by RT-PCR or real-time RT-PCR^{27,30,31}. Inapparent
140 infections were identified with a ≥ 4 -fold increase in iELISA titer among participants who did not
141 present with illness to the study Health Center between annual samplings. In a subset, the
142 serotype responsible for the inapparent infections that occurred before 2016 was identified by
143 neutralization assays (DENV1-4) and/or a multiplex Luminex-based assay (E domain III [EDIII] of
144 DENV1-4 and ZIKV) by comparing the antibody profile in the annual samples collected before
145 and after the infection. Inapparent infections detected in 2016-2019 were attributed to DENV2
146 based on laboratory and epidemiological data showing the circulation of only DENV2 in Nicaragua
147 during these years.

148 We selected 127 DENV-immune children who subsequently developed an inapparent
149 infection (n=64) or symptomatic infection (n=63) and analyzed their pre-infection plasma samples.
150 Samples obtained after a single DENV infection are referred to as post-primary infection samples,

151 while samples obtained after two or more DENV infections are referred to as post-secondary
152 infection samples (Figure 1).

153 **Cell lines**

154 Vero cells (ATCC CCL-81), Vero cells stably expressing human furin (Vero-Furin; kind gift of
155 Victor Tse and Ralph Baric, University of North Carolina (UNC), Chapel Hill)³², and Vero cells
156 expressing DC-SIGN (Vero DC-SIGN) were maintained in minimum essential medium (MEM;
157 Gibco) with 5% fetal bovine serum (FBS) supplemented with 1X non-essential amino acids
158 (Gibco), 1X sodium pyruvate (Gibco), and 1X penicillin-streptomycin (Gibco) at 37°C in 5% CO₂.

159 **Generation of Vero DC-SIGN cell line**

160 Vero cells were transduced using lentivirus to express DC-SIGN (CD209). DC-SIGN surface
161 expression was confirmed by flow cytometry using a PE-conjugated mouse anti-CD209 antibody
162 (BD Bioscience) for cell surface staining. A stock of Vero cells expressing surface DC-SIGN
163 receptors at >95% was generated by cell sorting using the BD Influx™ cell sorter and the BD
164 FACSDiva™ 8.0.1 software (BD Biosciences).

165 **Virus production**

166 DENV1 (5575.10a1SPD1), DENV2 (8891.12a1SPD2) and DENV3 (6629.10a1SPD3) are clinical
167 isolates from Nicaragua, isolated on C6/36 cells and passaged twice in Vero cells prior to
168 production of working stocks. Partially mature and mature viruses were grown in Vero and Vero-
169 Furin cells, respectively, in the same growth medium described above. Virions were harvested 5
170 days post-infection and frozen at 80°C until use.

171 **Viral titer**

172 Infectious titers were determined using a standard focus-forming assay³³. Briefly, Vero and Vero
173 DC-SIGN cells were infected with serial dilutions of virus and incubated at 37°C for 42-48 hours
174 (h) depending on the virus strain. Cells were fixed, permeabilized with 0.5% Triton for 6 minutes,

175 and stained with primary mouse anti-FL monoclonal antibody (mAb) 4G2 for 1.5h, washed 2 times
176 with PBS BSA 1%, and incubated with a goat anti-mouse secondary antibody conjugated to
177 horseradish peroxidase for 1h at room temperature. Foci were developed using True Blue HRP
178 substrate (KPL) and were counted using an CTL Immunospot analyzer (Cellular Technology,
179 Ltd.). The titer in focus forming units (FFU) per ml was then calculated based on the average of
180 replicates.

181 **Viral genome quantification and calculation of infectivity**

182 Viral RNA (vRNA) was extracted from virus particles using the QIAmp kit (QIAGEN). The PCR
183 standard curve used for the quantification of DENV copy genome was obtained with an amplicon
184 containing a synthetic cDNA encompassing a fragment of the 3'UTR region (nucleotides 10361–
185 10660) from DENV2 NI15. Pan-DENV primers (F – TTGAGTAAACYRTGCTGCCTGTAGCTC; R
186 - GAGACAGCAGGATCTCTGGTCTYTC,) were used to amplify the 3'UTR region encompassing
187 nucleotides 10361–10660 of the genome of DENV clinical isolates used in this study. To assess
188 the proportion of infectious viral particles in each of the virus stocks, viral titers obtained in different
189 cell lines were plotted against the number of RNA copies present in each dilution of virus studied.
190 Specific infectivity was calculated as the number of RNA molecules required for each infection
191 event (vRNA:FFU).

192 **Assessment of virion maturation state**

193 For each serotype, equal numbers of vRNA genome equivalents (GE) of partially mature and
194 mature viral stocks were diluted in 6X Laemmli sample buffer, boiled at 95°C for 5 minutes, and
195 subjected to SDS-PAGE electrophoresis on a 4-20% gradient gel. Proteins were then transferred
196 to a PVDF membrane and blocked using a blocking buffer containing 5% non-fat milk in PBS +
197 0.1% Tween-20 (PBS-T). The membrane was incubated with a purified human anti-E FL mAb
198 (1M7) and anti-prM mAbs (2G3, 1E23 and 2H21) at 0.1ug/ml in blocking buffer at 4°C overnight.
199 Antigen-antibody complexes were detected using donkey anti-human IgG conjugated to
200 horseradish peroxidase (HRP; 1:5000, Biolegend) in blocking buffer for 1h at room temperature.

201 After washing, membranes were developed in Supersignal West Pico PLUS Chemiluminescent
202 Substrate (ThermoFisher). Western blot images were captured with a ChemiDoc XRS+ system
203 (Bio-Rad). The pixel intensity of individual bands was measured using FIJI software, and relative
204 maturation was calculated by using the following equation: $(prM_{Vero\ Furin}/E_{Vero\ Furin})/(prM_{Vero}/E_{Vero})$.

205 **Neutralization assay**

206 The focus reduction neutralization test (FRNT) assay was conducted using Vero or Vero DC-
207 SIGN cells. Briefly, cells were seeded in a 96-well plate one day before infection. Serum/plasma
208 or mAbs were serially diluted and mixed with an equal inoculum of DENV (equivalent to 40-50
209 FFU/well for Vero and 150-200 FFU/well for Vero DC-SIGN cells) at a volume ratio of 1:1 to form
210 immune complexes. The virus-antibody mixture was incubated for 1h at 37°C in 5% CO₂. Cell
211 substrate growth medium was removed, and the virus-antibody mixture was added to Vero or
212 Vero DC-SIGN cells and incubated for 1h at 37°C in 5% CO₂. Subsequently, a 0.6%
213 carboxymethylcellulose overlay was added, and the plates were incubated for 48h. Foci were
214 developed and counted as described above. Foci counts were fitted using a variable slope dose
215 response curve using Graphpad, and neutralizing antibody titer (NT₅₀) values were calculated
216 with constrained top and bottom values of 100 and 0, respectively. Percent relative infection was
217 calculated as a ratio of foci counts in each serial dilution to the foci counts from the final serial
218 dilution of each sample. All samples and mAbs were run in duplicate with reported values required
219 to have an R² > 0.85 and a Hill slope > 0.5. Neutralization titers were measured against the
220 heterotypic incoming serotype of each participant.

221 **Statistical analysis**

222 NT₅₀ values were obtained using GraphPad software as indicated above. Statistical analysis was
223 performed in R software. Normal distribution of data was tested using the Shapiro-Wilk test.
224 Adjusted p-values and statistical significance of nAb titer magnitude and differential NT₅₀
225 comparisons were computed using the Wilcoxon test with Benjamini Hochberg correction.
226 Adjusted p-values and statistical significance of nAb potency across neutralization assay

227 conditions were computed using the paired Wilcoxon test with Benjamini Hochberg correction to
228 identify changes in antibody quality.

229 Receiver Operator Curve (ROC) analysis was performed using the pROC package
230 (v.1.18.0) in R studio (v. 2022.12.0+35). The pooled area under the curve (AUC), sensitivity and
231 specificity to detect a subsequent symptomatic infection was estimated across different assay
232 conditions. The cut-off of the assay was defined as the NT₅₀ value under which at least 90% of
233 the subsequent symptomatic infections were detected (sensitivity). The specificity corresponded
234 to the proportion of inapparent infections above this same value. A stratified analysis was also
235 conducted to evaluate the differential performance of the assay conditions according to incoming
236 infecting serotype (DENV1, DENV2 and DENV3). Finally, a logistic regression model was
237 constructed using the *stats* package v.4.2.2 and the *oddsratio* package v. 2.0.1 in R studio. We
238 assumed a binomial distribution of the response variable and a significance level (alpha) of 5%.
239 We estimated the odds ratio (OR) of developing a subsequent symptomatic versus inapparent
240 infection given an increment of 10² in the NT₅₀. Power calculations were conducted using the *pwr*
241 package v. 1.3-0. The package *pscl* v 1.5.5 was used for estimating the McFadden's pseudo R-
242 squared of each model.

243

244 **Results**

245 **Participants and DENV infections**

246 In this study, we analyzed pre-infection samples from 127 participants in the PDCS in Managua,
247 Nicaragua^{6,25}. These samples were collected 6-12 months before an inapparent DENV infection
248 (pre-inapparent group, n=64) or before a symptomatic infection (pre-symptomatic group, n=63)
249 (Fig.1). All participants included in the study had previously experienced DENV infection and had
250 developed anti-DENV antibodies (i.e., DENV-immune).

251 **Characterization of virus maturation state and infectivity**

252 To evaluate how the neutralization potency of serum antibodies is affected by DENV maturation
253 state, we first generated partially mature and mature virion stocks using clinical isolates of

254 DENV1, DENV2, and DENV3 from Nicaragua. The maturation state of these virions was
255 confirmed by analyzing the prM content in each virus stock via Western blot analysis. We
256 observed significant prM levels in viruses grown in standard Vero cells, indicative of a partially
257 mature phenotype (Fig. S1A). In contrast, production of the same parental viruses in furin-
258 overexpressing cells led to a substantial increase in maturation, as evidenced by low to
259 undetectable levels of prM (Fig. S1A). To further validate virion maturation state, we performed
260 FRNT using anti-FL mAbs (1M7, 4G2), which neutralize partially mature virions better than mature
261 virions¹⁰. As expected, virions grown in Vero-furin cells exhibited greater resistance to
262 neutralization by anti-FL mAbs, requiring higher concentrations for neutralization compared to
263 virions grown in standard Vero cells (Fig. S1C-D). These results demonstrated that viruses grown
264 in furin-overexpressing Vero cells were more mature than those grown in standard Vero cells.
265 Henceforth, we will refer to viruses grown in standard and furin-overexpressing Vero cells as
266 "partially mature" and "mature" virions, respectively.

267 We then evaluated the infectivity of both partially mature and mature DENV1, DENV2, and
268 DENV3 on standard Vero cells and Vero cells expressing the cellular attachment factor DC-SIGN.
269 This C-type lectin receptor plays a pivotal role in DENV biology by facilitating cell entry through
270 interaction with the N67 glycan on the envelope protein¹⁷. Viral infectivity was quantified by
271 determining the ratio of physical particle (vRNA) equivalents to focus forming units (FFU) (Fig.
272 S1B). As anticipated, the presence of DC-SIGN on the surface of Vero cells enhanced the
273 infectivity of both partially mature and mature DENV stocks, indicating that DC-SIGN provides an
274 alternative and potentially more favorable entry pathway for DENV. Importantly, the lowest
275 infectivity (10^3 - 10^4 vRNA:FFU) was observed using partially mature virions with standard Vero
276 cells, corresponding to the conditions of the reference neutralization assay. In contrast, the
277 highest infectivity (10^2 - 10^3 vRNA:FFU) was observed using mature virions with Vero DC-SIGN
278 cells (Fig. S1B). These results show that under reference assay conditions, DENV virions exhibit
279 infectivity levels approximately ten times lower compared to conditions that more closely resemble
280 the DENV maturation state and entry pathway *in vivo*.

282 **Cell substrate and DENV maturation state impact neutralization titer**

283 Given the substantial influence of maturation state and cellular substrate/entry pathway on DENV
284 infectivity, we next wanted to evaluate how these parameters impact the measurement of
285 neutralizing antibody titers (NT_{50}), which are often used as a surrogate for protection against
286 dengue disease. To address this question, we used pre-infection samples from the 127 DENV-
287 immune participants included in this study, collected prior to a subsequent DENV infection, and
288 evaluated how the neutralization potency of antibodies from each participant varied across four
289 assay conditions: partially mature DENV with Vero cells, partially mature DENV with Vero DC-
290 SIGN cells, mature DENV with Vero cells, and mature DENV with Vero DC-SIGN cells (Fig. 2A).
291 In each case, NT_{50} titers were measured against the heterotypic incoming serotype of each
292 participant and compared using a paired Wilcoxon test. For instance, the NT_{50} of serum samples
293 from participants collected prior to a DENV1 infection was measured using DENV1, while the NT_{50}
294 of serum samples from participants collected prior to a DENV2 infection was measured using
295 DENV2, etc.

296 Our results demonstrate that overall, NT_{50} values were significantly lower in assays
297 performed with mature virions compared to partially mature virions, indicating that serum
298 antibodies had a lower potency for neutralizing the incoming DENV virion in its mature form.
299 Additionally, NT_{50} values were lower in assays performed on Vero DC-SIGN cells compared to
300 Vero cells (Fig. 2B), indicating a decrease in the potency of nAbs under conditions that facilitate
301 glycan-mediated DENV entry. Notably, the most significant difference in median NT_{50} values was
302 observed between assays performed using Vero cells infected with partially mature virions
303 (reference assay condition, $NT_{50}=202$) and those using Vero DC-SIGN cells infected with mature
304 virions ($NT_{50}=42$).

305 These findings underscore the significant impact of virion maturation state and cell
306 substrate on the measurement of nAbs titers. Furthermore, they suggest that under reference
307 assay conditions, the potency of cross-reactive nAbs from the same participant may be
308 overestimated compared to neutralization assays performed with more mature virions and in the
309 presence of DC-SIGN.

310 **High pre-existing cross-reactive neutralizing antibodies titer is associated with protection**
311 **from dengue disease**

312 We next investigated whether pre-infection nAb titers are associated with protection from dengue
313 disease. We compared the NT₅₀ of pre-inapparent (n=64) versus pre-symptomatic (n=63) DENV
314 infection samples using the four assay conditions described previously. Our observations
315 revealed a significantly higher NT₅₀ in the pre-inapparent group, composed of individuals who
316 were protected against dengue disease, as compared to the pre-symptomatic group across all
317 four conditions, including the reference assay condition (Fig. 3A). This finding aligns with our
318 previous studies⁷ and supports that, overall, higher nAb titers are associated with protection from
319 symptomatic dengue.

320 To further analyze whether the NT₅₀ magnitude was associated with lower risk of a
321 subsequent symptomatic DENV infection, we performed a logistic regression model for each
322 assay condition. Consistently, a higher NT₅₀ was associated with lower risk of developing a
323 subsequent symptomatic disease when the assay was performed using partially mature virions
324 (OR 0.86, 95% Confidence Interval [CI] 0.75-0.96) or mature virions (OR 0.82, 95% CI 0.70-0.94)
325 on Vero cells, as well as for partially mature virions (OR 0.85, 95% CI 0.73-0.96) and mature
326 virions (OR 0.72, 95% CI 0.53-0.92) on Vero DC-SIGN cells (Table 3). Taken together, these
327 results demonstrate that higher pre-existing cross-reactive nAb titers are correlated with lower
328 risk of developing a subsequent symptomatic infection.

329 **High cross-reactive neutralizing antibody titer is associated with protection from dengue**
330 **disease in participants who have experienced a single prior DENV infection, but not in**
331 **those who have had two or more DENV infections.**

332 Next, we interrogated the impact of prior immunity on protection from subsequent dengue disease
333 by stratifying participants by their infection history. At the time of sample collection, 75/127
334 participants had experienced a single DENV infection (primary infection), and 53/127 participants
335 had experienced two or more DENV infections (secondary infection). In the pre-inapparent group,
336 34/64 individuals had previously experienced a primary infection, while 30/64 had previously had

337 secondary infection(s). In the pre-symptomatic group, 41/63 individuals had experienced a
338 previous primary infection and 22/63 had had secondary infection(s) (Table 1). Samples collected
339 from participants with prior primary infection will be referred to as “post-primary” (Post-1°), while
340 samples collected from participants who previously had had two or more DENV infections will be
341 referred to as “post-secondary” (Post-2°).

342 In participants with a prior primary DENV infection, we observed significantly higher NT₅₀
343 values in the pre-inapparent group compared to the pre-symptomatic group across all four
344 conditions (Fig. 3B). This suggests that high titers of cross-reactive nAbs are associated with
345 protection from disease upon a second DENV infection. However, in the post-secondary group,
346 both pre-inapparent and pre-symptomatic participants exhibited high NT₅₀ titers with no significant
347 difference in titer magnitude (Fig. 3B). Notably, we observed that the titers in participants from the
348 post-secondary pre-symptomatic infection group were as high as the titers observed in
349 participants with one prior infection who were protected against a subsequent symptomatic
350 infection (Post 1° pre-inapparent group) (Fig. 4B). This showed that high nAb titers alone are not
351 sufficient for conferring protection, implying that other aspects of the nAb response beyond
352 magnitude, or even beyond neutralization potency, may play a role in protection after secondary
353 DENV infection.

354 Consistently, in the post-primary infection group, the NT₅₀ assessed using Vero cells with
355 partially mature virions (OR 0.75, 95% CI 0.58-0.93) and mature virions (OR 0.79, 95% CI 0.63-
356 0.97), as well as the NT₅₀ assessed using Vero DC-SIGN cells with partially mature virions (OR
357 0.73, 95% CI 0.55-0.92) and mature virions (OR 0.31, 95% CI 0.12-0.65), were associated with
358 lower risk of subsequent symptomatic DENV infection using our logistic regression model.
359 However, in the post-secondary infection group, none of the NT₅₀ titers assessed were associated
360 with protection.

361 Collectively, these findings highlight that the association between nAb titer magnitude and
362 protection against symptomatic DENV infection depends on the infection history of participants.
363 Moreover, they suggest that while robust production of cross-reactive nAbs (magnitude) is a
364 critical factor in protection against a second DENV infection, it appears insufficient to confer

365 protection against subsequent infections. This implies that other nuanced aspects within or
366 beyond the nAb response might contribute more to protection in individuals with secondary DENV
367 infection histories.

368 **Maturation state- and DC-SIGN-sensitive antibodies are potential drivers of symptomatic**
369 **infection outcome after secondary infection**

370 In light of these observations, we leveraged the different assay conditions to gain insight into the
371 composition of nAb response. To do so, we compared the neutralizing potency of nAbs from each
372 participant across paired assay conditions. Specifically, comparison of the NT₅₀ measured using
373 partially mature *versus* mature virions was used to evaluate the contribution of antibodies that are
374 maturation state-dependent, while comparison of NT₅₀ measured on standard Vero *versus* Vero-
375 DC-SIGN cells was used as a proxy to evaluate whether neutralization was mediated by
376 antibodies capable of neutralizing DENV through N-glycan-mediated entry.

377 As previously mentioned, we did not observe any significant difference in the magnitude
378 of NT₅₀ from post-primary *pre-inapparent* infection individuals (i.e., protected) and post-secondary
379 *pre-symptomatic* infection individuals (i.e., not protected) across all four conditions tested.
380 Consequently, we found these two groups particularly intriguing and compared them, along with
381 post-secondary pre-symptomatic individuals, to investigate whether variations in nAb *composition*
382 were associated with different outcomes. (Fig. 4A, B). Among the characteristics that set the
383 group of pre-symptomatic participants apart, we found that, unlike both pre-inapparent infection
384 groups (Post-1° and Post-2°), the neutralization potency of post-secondary pre-symptomatic
385 infection samples was significantly lower when using mature virions compared to partially mature
386 virions in Vero cells (maturation-sensitive nAbs). Similarly, lower neutralization potency was
387 observed when using partially mature virions to infect DC-SIGN-expressing Vero cells compared
388 to standard Vero cells in post-secondary pre-symptomatic infection samples (see Fig. 4C). This
389 underscores the variations that exist in the composition of the nAbs between protected and
390 unprotected individuals. Specifically, serum samples from participants protected against dengue
391 disease were characterized by cross-reactive nAbs that exhibited equal potency against both
392 mature and partially mature virions in Vero cells, and in the presence or absence of DC-SIGN. In

393 contrast, the nAb repertoire/composition of sera from participants who experienced symptomatic
394 infection (Post-2° pre-symptomatic) was marked by nAbs sensitive to maturation state and the
395 presence of DC-SIGN.

396 This finding supports that factors beyond the magnitude of nAb titers may play a
397 substantial role in conferring protection against symptomatic dengue disease and emphasizes the
398 importance of considering antibody quality, in addition to magnitude, when studying correlates of
399 protection against dengue disease.

400 **Neutralizing antibody magnitude associates with protection against dengue disease in a** 401 **serotype-dependent manner**

402 We next investigated if the association of cross-reactive nAb titer with disease protection was
403 similar when the infecting serotype was DENV1, DENV2 or DENV3. To address this question, we
404 stratified the analysis by incoming DENV serotype. Our study included 19 individuals with
405 subsequent post-primary DENV1 infections, 61 individuals with subsequent DENV2 infections,
406 and 47 individuals with subsequent DENV3 infections (Table 2). In the pre-DENV1 infection group
407 (Fig. 5A, top row), which includes only post-primary infection individuals, higher nAb titers were
408 observed in the pre-inapparent group using neutralization assays with mature virions on standard
409 Vero cells and partially mature virions on both standard Vero and Vero DC-SIGN cells.

410 In the pre-DENV2 infection group, significantly higher nAb titers were observed in the pre-
411 inapparent individuals across all conditions (Fig. 5A, middle row) when samples were not stratified
412 by infection history. However, after stratification (Fig. 5B), only nAb titers assessed in standard
413 Vero and Vero DC-SIGN cells using mature virions were correlated with protection from
414 symptomatic infection in the post-primary group (n=29) (OR 0.62, 95% CI 0.38-0.88; OR 0.09,
415 95% 0.01-0.52, respectively) and with mature virions in standard Vero cells in the post-secondary
416 group (n=32) (OR 0.72, 95% CI, 0.5-0.95) (Fig. 5B and Table S1).

417 In contrast, in the pre-DENV3 infection group (Fig. 5A, bottom row), the magnitude of nAb
418 titers was not significantly different between subsequent symptomatic and inapparent infection
419 regardless of assay condition or infection history (Fig. S2).

420 In summary, our findings reveal serotype-specific variation in protection against dengue
421 disease. Higher pre-infection levels of cross-reactive nAbs are associated with protection from
422 symptomatic DENV1 and DENV2 infections. However, this association was not observed in the
423 case of DENV3, suggesting that disease protection in the context of DENV3 infections might
424 involve other aspects of the immune response.

425 **Pre-infection neutralizing antibody composition differentially impacts outcome by DENV** 426 **serotype and infection history**

427 To assess how variations in nAb composition in pre-infection sera relate to protection from
428 symptomatic DENV infection for each serotype, we used paired Wilcoxon tests to compare the
429 neutralization potency of samples stratified by serotype across assay conditions. In post-*primary*
430 pre-DENV1, pre-DENV2, and pre-DENV3 symptomatic individuals (Fig. 6A,B,C; Fig. S3), we
431 observed significant differences in NT₅₀ titer when FRNT assays were performed using partially
432 mature virions with standard Vero compared to Vero DC-SIGN cells. These findings indicate that
433 antibodies present in pre-symptomatic infection samples are less potent for neutralizing DENV
434 when cell entry is glycan-mediated (i.e., interacting with DC-SIGN on the target cell). This
435 suggests a difference in nAbs composition, with pre-symptomatic post-primary DENV infection
436 individuals having less nAbs able to block DC-SIGN-mediated entry. In contrast, in post-
437 *secondary* pre-DENV2 infection samples (Fig. 6D), a significant reduction in NT₅₀ titer was
438 observed in pre-symptomatic infection samples when FRNT assays were performed in standard
439 Vero cells using partially mature versus mature DENV2 virions. This suggests a difference in nAbs
440 composition, with post-secondary pre-symptomatic DENV2 individuals having more nAbs
441 sensitive to maturation state. Interestingly, no difference in nAb quality was observed in post-
442 secondary pre-DENV3 infections.

443 **Assay condition impacts cross-reactive neutralizing antibodies titer cut-off to distinguish** 444 **subsequent inapparent and symptomatic DENV infections**

445 Since the identification of individuals who will develop a subsequent symptomatic infection is

446 relevant for vaccine design, we evaluated the performance of the four assay conditions for
447 detecting a subsequent symptomatic DENV infection. We performed a ROC analysis to compare
448 the assay conditions in terms of their sensitivity and specificity (Table 3). The cut-off of the assay
449 was defined as the NT_{50} value under which at least 90% of the subsequent symptomatic infections
450 were detected (sensitivity). The specificity corresponded to the proportion of inapparent infections
451 above the cut-off value.

452 Notably, we found a substantial impact of assay condition on the test performance for
453 discriminating individuals who would subsequently develop a symptomatic versus inapparent
454 infection. The NT_{50} cut-off varied substantially, ranging from 180 for mature virions on Vero DC-
455 SIGN cells to 898 for partially mature virions on Vero cells (Table 3), and the maximum specificity
456 achieved was only 32% for the assay performed on mature virions with Vero cells (Table 3). For
457 the assay performed on partially mature virions on standard Vero cells, which is the assay used
458 in most clinical trials for vaccine testing, the NT_{50} cut-off for achieving a sensitivity of at least 90%
459 was 898.13. Nevertheless, at this titer, the specificity was only 8%. This means that, using this
460 assay, although more than 90% of the individuals had an NT_{50} below 898 before developing a
461 symptomatic DENV infection, 92% of the individuals that subsequently developed an inapparent
462 infection were also below this cut-off and yet were protected from disease.

463 When we stratified by infection history, all assay conditions effectively identified
464 subsequent symptomatic infections in the post-primary and post-secondary infection group with
465 at least 90% of sensitivity (Table 3). However, the specificity ranged from 29% to 35% in the post-
466 primary infection group, and from 10% to 21% in the post-secondary infection group. Interestingly,
467 mature virions with Vero DC-SIGN cells displayed the best performance in both groups (Table 3).
468 This reveals that in the context of natural infection, assessment of nAb titers are appropriate
469 screening tests for identifying individuals at risk for developing subsequent symptomatic DENV
470 disease, but they perform poorly for detecting protected individuals with subsequent inapparent
471 infection.

472

473 Discussion

474 In this study, we analyzed 127 individuals with known infection history who experienced
475 subsequent inapparent or symptomatic DENV infection from our long-standing cohort in
476 Nicaragua. We evaluated the effect of previous primary or secondary DENV immunity on the
477 quantity and quality of the cross-reactive nAb response by controlling key parameters of the
478 neutralization assay. We also assessed the association of nAb titer under different assay
479 conditions with probability of symptomatic DENV1, DENV2 or DENV3 infection. While we
480 confirmed that nAb titers overall are associated with protection against symptomatic DENV
481 infection⁷, we found important differences by infection history (i.e., prior primary versus secondary
482 immunity) and incoming serotype. We also show that the ability of nAb titers to identify individuals
483 at risk depends on DENV maturation state and cellular substrate in the neutralization assay.

484 Neutralizing antibodies are considered an essential component of the protective response
485 against flavivirus infections and are used to assess vaccine safety and efficacy^{34,35}. As a
486 quantitative functional antibody assay, the neutralization assay is considered the “gold standard”
487 for quantifying and characterizing DENV nAbs⁸. However, in routine laboratory practice as well
488 as in clinical trials, it is common to use virions grown in Vero or C6/36 cells⁸, although it has been
489 shown that DENV virions purified directly from human blood or produced in primary cells using
490 monocyte-derived dendritic cells are more mature than virions grown in cell culture-adapted
491 lines^{10,36}. To approach a virion state closer to the one observed during natural infection, furin-
492 overexpressing cell lines were generated and used to produce mature flavivirus stocks with low
493 prM content^{36,37}. This difference in maturation state changes the proportion and identity of
494 epitopes exposed and, thus, the number and type of antibodies required to completely neutralize
495 infectious particles^{11,16}. Consistent with published literature, we observed that plasma samples
496 showed a significantly lower neutralizing activity on mature virions compared to partially mature
497 virions grown in Vero cells, suggesting that neutralization titers may be overestimated under
498 standard FRNT conditions³⁸.

499 Glycan-mediated entry is an important aspect of DENV dissemination in humans^{39,40}, but
500 standard assay conditions using cells lacking C-type lectin receptors (e.g., DC-SIGN) do not

501 measure the contribution of nAbs that prevent N-glycan interactions. Unlike other flaviviruses, the
502 E protein of DENV has an additional glycosylation site at Asp-67 (EDI), which allows DENV to
503 enter cells through interaction with DC-SIGN¹⁷. As we and others have shown^{17,41}, DC-SIGN is a
504 key attachment factor for DENV and expressing it on the surface of Vero cells significantly
505 increases DENV infectivity. DC-SIGN is expressed on dendritic cells (DCs) and monocytes^{18–20}
506 and is associated with DENV pathogenesis. Nevertheless, while nAbs that impede DC-SIGN-
507 mediated viral entry could limit viral dissemination and promote the establishment of a rapid and
508 effective cell-mediated immune response²⁰, this parameter is rarely considered when studying
509 antibody-mediated protection against dengue disease. In this study, we assessed the effect of
510 DC-SIGN expression on Vero cells to measure nAbs able to block the N-glycan-mediated entry
511 pathway. As expected, nAb titers were strongly affected (decreased) by the expression of DC-
512 SIGN, and the reduction in cross-reactive nAb potency was even greater when assays were
513 performed using mature virions. Similar results were previously published using another flavivirus
514 closely related to DENV, West Nile virus, together with DC-SIGNR expressing-cells¹¹. We found
515 that when mature virions are used with Vero DC-SIGN cells, 90% of the subsequent symptomatic
516 infections can be identified with a lower NT₅₀ cutoff than with other assay conditions, particularly
517 in post-primary infections. This shows that more serum antibodies are required to neutralize *in*
518 *vitro* assays with more physiologically relevant viruses and cells. Thus, anti-DENV nAb titers are
519 likely overestimated when measured in standard Vero cell-based assays and virions with a
520 maturation state different from the virions that antibodies encounter in the bloodstream during
521 infection. These findings highlight the importance of selecting an appropriate cell substrate and
522 virion maturation state to support vaccine development and evaluate efficacy.

523 Consistent with previous reports^{7,42}, we observed significantly higher nAb titers in
524 participants before an inapparent DENV infection as compared to before a symptomatic DENV
525 infection when analyzing the entire sample set. However, after stratification by post-primary
526 versus post-secondary DENV infection history, we found that the magnitude of the nAb response
527 only significantly correlated with protection after prior primary infection, although the direction of
528 the effect was similar for post-secondary infections. Further, we observed differences in

529 association with infection outcome when stratifying by incoming serotype. Higher magnitude of
530 pre-infection nAb titer was associated with protection from subsequent symptomatic infection with
531 DENV1 or DENV2, but not with DENV3 in any of the assay conditions or infection histories.
532 Interestingly, in a recent study investigating potential additional antibody characteristics that could
533 play a protective role, we found that antibody-dependent complement deposition (ADCD) and
534 complement- and antibody-mediated virolysis were associated with protection from symptomatic
535 disease in samples collected prior to a subsequent DENV3 infection⁴³. Here, we also found that,
536 while their nAb titer magnitude was similar, the neutralizing activity of post-secondary pre-
537 symptomatic infection individuals was primarily driven by both DC-SIGN-sensitive and maturation
538 state-dependent Abs, while the neutralizing potency of post-primary pre-inapparent infection was
539 not. This suggests that variations in the composition of the antibody repertoire exist in the
540 protected versus unprotected groups and that a difference in nAb quality might be associated with
541 disease outcome.

542 In addition, while 90% of the subsequent symptomatic infections in our study had pre-
543 infection NT₅₀ titers below the NT₅₀ threshold identified via ROC analysis, a substantial proportion
544 of pre-inapparent infection individuals did not reach this cutoff either, yet they did not develop a
545 symptomatic infection. This suggests that although nAbs play a role in protection against
546 symptomatic disease, the magnitude of nAb titers is not a robust parameter to differentiate
547 protected individuals from those at risk of developing a symptomatic infection and that other
548 components of the immune response may play an even more important role. This suggests that
549 the measurement of nAb quality and other antibody Fc functions such as ADCD or virolysis⁴³ may
550 serve as correlates of protection, which could be used in addition to neutralization assays toward
551 the design and evaluation of dengue vaccines, as well as other components of the immune
552 response such as T cells.

553 The strengths of our study include the unique sample set that allowed us to evaluate the
554 effects of neutralization assay condition on the outcome of DENV infection in natural populations.
555 Samples from diverse epidemics allowed us to observe the distinctions in contribution of cross-
556 reactive nAbs to protection from subsequent symptomatic infection depending on infection history

557 and incoming serotype, which have not been reported previously. We also used clinical isolates
558 representing circulating strains in the study population, which is important because highly
559 passaged reference strains are cell line-adapted and have accumulated mutations that can
560 change their antigenic landscape^{10,44}. In contrast, many vaccine studies and research laboratories
561 frequently use WHO reference strains that do not match the genotypic and phenotypic features
562 of the contemporary DENV strains^{33,45}.

563 Nevertheless, our study has limitations. First, since we studied sequential DENV infections
564 in natural populations, we evaluated the role of cross-reactive nAbs in protection, but were not
565 able to assess type-specific nAbs, which are often the focus of studies of vaccine efficacy⁵.
566 Nonetheless, many of our findings and overall conclusions are relevant for studies of immune
567 correlates of dengue. Second, as our study population is from Nicaragua over a 15-year period,
568 our analysis is naturally limited to the circulating serotypes and epidemiology of DENV in the
569 timeframe and area of study. Further, we were not able to address the impact of different
570 sequences of infections in the composition of the nAb response due to small sample sizes of
571 specific serotype sequences. Third, although anti-DENV antibodies can also have infection-
572 enhancing properties, we do not measure this here since we focus on studying the neutralizing
573 capacity of antibodies using cell substrates that do not express Fcγ receptors that can mediate
574 antibody-dependent enhancement⁴⁶. Lastly, our current sample size is under-powered for the
575 predictive model of risk of symptomatic disease for incoming DENV1 or DENV3 infection.
576 Nonetheless, the observed differences in effect sizes imply that for achieving a power of at least
577 80% we would need only 28 pre-DENV1 infection individuals, in contrast with 231 pre-DENV3
578 infection individuals and a total of 222 individuals in the post-secondary infection group. These
579 differences in the required sample size are evidence of the potential negligible role of nAbs in
580 protection against DENV3 symptomatic infection and upon a post-secondary infection.

581 In conclusion, we have identified serotype-specific differences in the association of nAbs
582 with protection against symptomatic infection. Higher NT₅₀ titers were associated with protection
583 against symptomatic DENV infection in participants with one prior DENV infection, but only
584 against DENV2 in those with multiple prior infections. nAbs were correlated with protection from

585 symptomatic DENV1 and DENV2 infections but not DENV3. Thus, the unique features of our
586 cohort sample set allowed us to identify the role of infection history in shaping the protective
587 potency of nAbs, as well as the relevance of the incoming serotype, ultimately revealing the
588 heterogeneity and the complexity of immune interactions among DENV serotypes. Comparing
589 different assay conditions, we found that maturation state- and DC-SIGN-sensitive nAbs may be
590 less protective against symptomatic DENV infection. More studies are needed to assess the
591 effects of these variables, as well as the impact of WHO reference strains compared to clinical
592 isolates, in the context of vaccine studies. Finally, although nAbs correlate with protection under
593 specific circumstances, our findings reveal that they do not capture the full breadth of the
594 protective immune response, thus implying an important role for other aspects of the antibody
595 and broader immune response in generation and evaluation of protection from symptomatic
596 dengue. Incorporating a broader range of immune parameters in serological assays will enable a
597 more comprehensive evaluation of immune correlates of protection.

598 **Funding**

599 This work was supported by the National Institute of Allergy and Infectious Diseases/National
600 Institutes of Health (NIAID/NIH) via grant P01AI106695 (E.H.). The PDCS study was supported
601 by NIAID/NIH grants U01AI153416 (E.H.) and U19AI118610 (E.H.), R01AI099631 (A.B.), the
602 Pediatric Dengue Vaccine Initiative grant VE-1 (E.H.) from the Bill and Melinda Gates Foundation,
603 and NIH subcontract HHSN2722001000026C (E.H.). L.C.K. was supported by the Intramural
604 Research Program of NIAID/NIH.

605 **Acknowledgments**

606 We are grateful for the PDCS participants and their families. We appreciate the hard work and
607 dedication of the past and present members of the study team at the Centro de Salud Sócrates
608 Flores Vivas, the Sustainable Sciences Institute in Nicaragua, and the Laboratorio Nacional de
609 Virología in the Centro Nacional de Diagnóstico y Referencia. We thank Scott Biering and Richard
610 Ruan for generating the Vero-DC-SIGN cells.

611 **Author contributions**

612 S.B and E.H conceived the project. S.B. and A.G. designed the experiments. A.G., E.D., R.M-H
613 and T.S. carried out the experiments. J.V.Z, J.A.R managed the clinical and laboratory databases
614 and organized the data for analysis. G.K and A.B. directed the cohort study. S.B, A.G, E.D, J.C.O,
615 L.K, A.S. and E.H contributed to the analysis and interpretation of the results. E.H. obtained
616 funding. S.B, A.G., J.C.O and E.H., wrote the manuscript with input from all authors. All authors
617 provided critical feedback and helped shape the research, analysis and manuscript.

618 **Inclusion & Ethics**

619 This research is embedded in a long-term 35-year close collaboration with Nicaraguan colleagues
620 that has included multiple aspects of scientific capacity building and enhancement, as well as
621 supporting improvement of physical research infrastructure. With regards to this study, local
622 Nicaraguan researchers were included throughout the research process – in study design, study
623 implementation, data ownership, and authorship of publications. Four of the authors on this
624 publication are from the local team in Nicaragua. The research is locally relevant, and this was
625 determined in collaboration with local partners in Nicaragua. We discussed roles and
626 responsibilities amongst collaborators ahead of the research, and we conducted capacity-building
627 in the form of additional on-site training of local researchers in virus production and neutralization
628 assays. The parent cohort study has been approved initially and every year thereafter (currently
629 in its 20th year) by a local ethics review committee. This research does not result in stigmatization,
630 incrimination, discrimination, or otherwise personal risk to participants nor any health, safety,
631 security or other risk to researchers. Benefit sharing measures related to transfer of biological
632 materials been discussed with our partners in Nicaragua. Finally, we have taken local and regional
633 research relevant to our study into account in citations.

634 **Data and Material availability**

635 All data produced in the present study are available by request, as is required by the Institutional
636 Review Board-approved protocol for the Pediatric Dengue Cohort Study. Please contact Dr. Eva
637 Harris (eharris@berkeley.edu) and/or the committee for the Protection of Human Subjects at
638 University of California Berkeley (510-642-7461; ophs@berkeley.edu). Data analysis was
639 performed using R and packages that are publicly available. Any transfer of materials needs to
640 be approved by the IRB and by Dr. Harris and Nicaraguan researchers. Further, the samples in
641 question are from pediatric participants in our long-term cohort study and are therefore very
642 limited in volume. Thus, these materials are subject to restriction based on limited availability. For
643 more information, please contact Dr. Harris and/or the committee for the Protection of Human
644 Subjects at University of California, Berkeley.

645 **References**

- 646 1. Cattarino, L., Rodriguez-Barraquer, I., Imai, N., Cummings, D. A. T. & Ferguson, N. M.
647 Mapping global variation in dengue transmission intensity. *Sci. Transl. Med.* **12**, (2020).
- 648 2. Katzelnick, L. C., Coloma, J. & Harris, E. Dengue: knowledge gaps, unmet needs, and
649 research priorities. *Lancet Infect. Dis.* **17**, e88–e100 (2017).
- 650 3. Salje, H. *et al.* Reconstruction of antibody dynamics and infection histories to evaluate
651 dengue risk. *Nature* **557**, 719–723 (2018).
- 652 4. Katzelnick, L. C. *et al.* Zika virus infection enhances future risk of severe dengue disease.
653 *Science* **369**, 1123–1128 (2020).
- 654 5. Sabchareon, A. *et al.* Protective efficacy of the recombinant, live-attenuated, CYD
655 tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
656 *Lancet* **380**, 1559–1567 (2012).
- 657 6. Katzelnick, L. C. *et al.* Antibody-dependent enhancement of severe dengue disease in
658 humans. *Science* **358**, 929–932 (2017).
- 659 7. Katzelnick, L. C., Montoya, M., Gresh, L., Balmaseda, A. & Harris, E. Neutralizing antibody
660 titers against dengue virus correlate with protection from symptomatic infection in a
661 longitudinal cohort. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 728–733 (2016).
- 662 8. Thomas, S. J. *et al.* Dengue plaque reduction neutralization test (PRNT) in primary and
663 secondary dengue virus infections: How alterations in assay conditions impact
664 performance. *Am. J. Trop. Med. Hyg.* **81**, 825–833 (2009).
- 665 9. Kuhn, R. J. *et al.* Structure of dengue virus: implications for flavivirus organization,
666 maturation, and fusion. *Cell* **108**, 717–725 (2002).
- 667 10. Raut, R. *et al.* Dengue type 1 viruses circulating in humans are highly infectious and poorly
668 neutralized by human antibodies. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 227–232 (2019).
- 669 11. Mukherjee, S. *et al.* Mechanism and significance of cell type-dependent neutralization of
670 flaviviruses. *J. Virol.* **88**, 7210–7220 (2014).
- 671 12. Yu, I.-M. *et al.* Structure of the immature dengue virus at low pH primes proteolytic

- 672 maturation. *Science* **319**, 1834–1837 (2008).
- 673 13. Stadler, K., Allison, S. L., Schlich, J. & Heinz, F. X. Proteolytic activation of tick-borne
674 encephalitis virus by furin. *J. Virol.* **71**, 8475–8481 (1997).
- 675 14. Li, L. *et al.* The flavivirus precursor membrane-envelope protein complex: structure and
676 maturation. *Science* **319**, 1830–1834 (2008).
- 677 15. Plevka, P. *et al.* Maturation of flaviviruses starts from one or more icosahedrally
678 independent nucleation centres. *EMBO Rep.* **12**, 602–606 (2011).
- 679 16. Nelson, S. *et al.* Maturation of West Nile virus modulates sensitivity to antibody-mediated
680 neutralization. *PLoS Pathog.* **4**, e1000060 (2008).
- 681 17. Mondotte, J. A., Lozach, P.-Y., Amara, A. & Gamarnik, A. V. Essential role of dengue virus
682 envelope protein N glycosylation at asparagine-67 during viral propagation. *J. Virol.* **81**,
683 7136–7148 (2007).
- 684 18. Schmid, M. A., Diamond, M. S. & Harris, E. Dendritic cells in dengue virus infection: targets
685 of virus replication and mediators of immunity. *Front. Immunol.* **5**, 647 (2014).
- 686 19. Hacker, K., White, L. & de Silva, A. M. N-linked glycans on dengue viruses grown in
687 mammalian and insect cells. *J. Gen. Virol.* **90**, 2097–2106 (2009).
- 688 20. Rodriguez-Madoz Juan R., Bernal-Rubio Dabeiba, Kaminski Dorota, Boyd Kelley &
689 Fernandez-Sesma Ana. Dengue Virus Inhibits the Production of Type I Interferon in
690 Primary Human Dendritic Cells. *J. Virol.* **84**, 4845–4850 (2010).
- 691 21. Durbin, A. P. *et al.* Phenotyping of peripheral blood mononuclear cells during acute dengue
692 illness demonstrates infection and increased activation of monocytes in severe cases
693 compared to classic dengue fever. *Virology* **376**, 429–435 (2008).
- 694 22. Hall, W. C. *et al.* Demonstration of yellow fever and dengue antigens in formalin-fixed
695 paraffin-embedded human liver by immunohistochemical analysis. *Am. J. Trop. Med. Hyg.*
696 **45**, 408–417 (1991).
- 697 23. Jessie, K., Fong, M. Y., Devi, S., Lam, S. K. & Wong, K. T. Localization of dengue virus in
698 naturally infected human tissues, by immunohistochemistry and in situ hybridization. *J.*
699 *Infect. Dis.* **189**, 1411–1418 (2004).

- 700 24. Schmid, M. A. & Harris, E. Monocyte recruitment to the dermis and differentiation to
701 dendritic cells increases the targets for dengue virus replication. *PLoS Pathog.* **10**,
702 e1004541 (2014).
- 703 25. Kuan, G. *et al.* The Nicaraguan Pediatric Dengue Cohort Study: Study Design, Methods,
704 Use of Information Technology, and Extension to Other Infectious Diseases. *Am. J.*
705 *Epidemiol.* **170**, 120–129 (2009).
- 706 26. Gordon, A. *et al.* The Nicaraguan pediatric dengue cohort study: incidence of inapparent
707 and symptomatic dengue virus infections, 2004-2010. *PLoS Negl. Trop. Dis.* **7**, e2462
708 (2013).
- 709 27. Lanciotti, R. S., Calisher, C. H., Gubler, D. J., Chang, G. J. & Vorndam, A. V. Rapid
710 detection and typing of dengue viruses from clinical samples by using reverse
711 transcriptase-polymerase chain reaction. *J. Clin. Microbiol.* **30**, 545–551 (1992).
- 712 28. Waggoner, J. J. *et al.* Homotypic Dengue Virus Reinfections in Nicaraguan Children. *J.*
713 *Infect. Dis.* **214**, 986–993 (2016).
- 714 29. Balmaseda, A., Sandoval, E., Pérez, L., Gutiérrez, C. M. & Harris, E. Application of
715 molecular typing techniques in the 1998 dengue epidemic in Nicaragua. *Am. J. Trop. Med.*
716 *Hyg.* **61**, 893–897 (1999).
- 717 30. Waggoner, J. J. *et al.* Development of an internally controlled real-time reverse
718 transcriptase PCR assay for pan-dengue virus detection and comparison of four molecular
719 dengue virus detection assays. *J. Clin. Microbiol.* **51**, 2172–2181 (2013).
- 720 31. Waggoner, J. J. *et al.* Single-Reaction Multiplex Reverse Transcription PCR for Detection of
721 Zika, Chikungunya, and Dengue Viruses. *Emerg. Infect. Dis.* **22**, 1295–1297 (2016).
- 722 32. Tse, L. V. *et al.* Generation of Mature DENVs via Genetic Modification and Directed
723 Evolution. *mBio* **13**, e0038622 (2022).
- 724 33. Martinez, D. R. *et al.* Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the
725 Neutralization Activity of Human Antibodies in Vaccinees. *Cell Rep.* **33**, 108226 (2020).
- 726 34. Dowd, K. A. & Pierson, T. C. Antibody-mediated neutralization of flaviviruses: a reductionist
727 view. *Virology* **411**, 306–315 (2011).

- 728 35. Pierson, T. C. & Diamond, M. S. Molecular mechanisms of antibody-mediated
729 neutralisation of flavivirus infection. *Expert Rev. Mol. Med.* **10**, e12 (2008).
- 730 36. Dejnirattisai, W. *et al.* A new class of highly potent, broadly neutralizing antibodies isolated
731 from viremic patients infected with dengue virus. *Nat. Immunol.* **16**, 170–177 (2015).
- 732 37. Mukherjee, S. *et al.* Enhancing dengue virus maturation using a stable furin over-
733 expressing cell line. *Virology* **497**, 33–40 (2016).
- 734 38. Maciejewski, S. *et al.* Distinct neutralizing antibody correlates of protection among related
735 Zika virus vaccines identify a role for antibody quality. *Sci. Transl. Med.* **12**, (2020).
- 736 39. Idris, F., Muharram, S. H. & Diah, S. Glycosylation of dengue virus glycoproteins and their
737 interactions with carbohydrate receptors: possible targets for antiviral therapy. *Arch. Virol.*
738 **161**, 1751–1760 (2016).
- 739 40. Hidari, K. I. P. J. & Suzuki, T. Antiviral agents targeting glycans on dengue virus E-
740 glycoprotein. *Expert review of anti-infective therapy* vol. 9 983–985 (2011).
- 741 41. Tassaneeritthep, B. *et al.* DC-SIGN (CD209) mediates dengue virus infection of human
742 dendritic cells. *J. Exp. Med.* **197**, 823–829 (2003).
- 743 42. Corbett, K. S. *et al.* Preexisting neutralizing antibody responses distinguish clinically
744 inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. *J. Infect.*
745 *Dis.* **211**, 590–599 (2015).
- 746 43. Dias, A. G., Jr *et al.* Antibody Fc characteristics and effector functions correlate with
747 protection from symptomatic dengue virus type 3 infection. *Sci. Transl. Med.* **14**, eabm3151
748 (2022).
- 749 44. VanBlargan, L. A. *et al.* Dengue Virus Serotype 1 Conformational Dynamics Confers Virus
750 Strain-Dependent Patterns of Neutralization by Polyclonal Sera. *J. Virol.* **95**, e0095621
751 (2021).
- 752 45. Gallichotte, E. N., Baric, R. S. & de Silva, A. M. The Molecular Specificity of the Human
753 Antibody Response to Dengue Virus Infections. *Adv. Exp. Med. Biol.* **1062**, 63–76 (2018).
- 754 46. Boonnak, K. *et al.* Role of dendritic cells in antibody-dependent enhancement of dengue
755 virus infection. *J. Virol.* **82**, 3939–3951 (2008).

756 **Figure Legends**

757 **Figure 1. Participant serological sampling schematic.** Plasma samples from DENV-immune
758 participants were collected before a subsequent DENV1, 2, or 3 infection and were stratified into
759 two separate groups according to disease outcome: Pre-inapparent (blue) and pre-symptomatic
760 (yellow).

761 **Figure 2. Cross-reactive nAb titers across assay conditions.** (A) Schematic of the different
762 neutralization assay conditions. (B) Neutralizing titers (NT₅₀) of 127 participants measured against
763 the incoming DENV serotype using virions of different maturation state and different cell substrate.
764 Median NT₅₀ values are indicated below each boxplot. Diamond indicates mean NT₅₀. Asterisks
765 indicate Benjamini Hochberg adjusted p-values for paired Wilcoxon test. p-values: ns, >0.05; *,
766 <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

767 **Figure 3. Cross-reactive nAb titers of pre-inapparent and pre-symptomatic DENV infection**
768 **samples.** (A) NT₅₀ of pre-inapparent (n=64) and pre-symptomatic (n=63) DNV infection groups
769 measured against the incoming serotype across FRNT assay conditions, and (B) NT₅₀ of pre-
770 inapparent and pre-symptomatic participants stratified by their infection history at the time of
771 sample collection (Post-1°: post-primary infection, Post-2°: post-secondary infection). Diamond
772 indicates mean NT₅₀. Asterisks indicate Benjamini Hochberg adjusted p-values for Wilcoxon test.
773 p-values: ns, >0.05; *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

774 **Figure 4. Comparison of nAb responses between pre-inapparent post-primary and post-**
775 **secondary versus pre-symptomatic post-secondary infection samples.** (A) Schematic of the
776 groups compared. (B) Magnitude of the nAb response using different virion maturation states and
777 cell substrates. (C) Impact of change in assay condition on the neutralization titers of participants.
778 Asterisks indicate Benjamini Hochberg adjusted p-values for Wilcoxon test (B) and paired
779 Wilcoxon test (C). p-values: ns, >0.05; *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

780 **Figure 5. Cross-reactive nAb titers of pre-inapparent and pre-symptomatic DENV infection**
781 **participants stratified by incoming serotype and infection history.** (A) NT₅₀ of pre-inapparent
782 and pre-symptomatic DENV infection groups across FRNT assay conditions stratified by incoming
783 serotype. (B) NT₅₀ of pre-DENV2 infection participants stratified by infection history. Diamond
784 indicates mean NT₅₀. Asterisks indicate Benjamini Hochberg adjusted p-values for Wilcoxon test.
785 p-values: ns, >0.05; *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

786 **Figure 6. Serotype-specific characteristics of the nAb response associated with DENV**
787 **infection outcome.** Impact of change in assay condition on the nAb response of pre-inapparent
788 and pre-symptomatic infection participants from the (A) post-primary pre-DENV1 infection group,
789 (B) post-primary pre-DENV3 infection group, and (C) post-secondary pre-DENV2 infection group.
790 Post-1°: post-primary infection, Post-2°: post-secondary infection. Asterisks indicate Benjamini
791 Hochberg adjusted p-values for paired Wilcoxon tests. p-values: ns, >0.05; *, <0.05; **, <0.01;
792 ***, <0.001; ****, <0.0001.

Figure 1





Figure 3

A.



B.




Figure 4








Figure 5**A.****B.**

Figure 6







Table 1. Pre-inapparent and pre-symptomatic infection participant characteristics.

	Pre-inapparent	Pre-symptomatic	p
n	64	63	
Age (mean (SD))	10.66 (2.81)	10.41 (3.56)	0.665
Male (%)	35 (55.6)	37 (60.7)	0.694
Infection history (%)			0.03
Primary (%)	34 (53.1)	41 (65.0)	
Secondary (%)	30 (46.9)	22 (35.0)	

Table 2. Participant characteristics stratified by incoming serotype and infection history

	DENV1	DENV2	DENV3	p
n	19	61	47	
Age (mean (SD))	9.93 (2.01)	11.29 (3.63)	9.83 (2.79)	0.044
Male (%)	11 (57.9)	34 (57.6)	27 (58.7)	0.994
Pre-symptomatic (%)	10 (52.6)	32 (52.5)	21 (44.7)	0.696
Pre-inapparent (%)	9 (47.4)	29 (47.5)	26 (55.3)	0.696
Infection history (%)				<0.001
Primary (%)	19 (100.0)	29 (47.5)	27 (57.4)	
Secondary (%)	0 (0.0)	32 (52.5)	20 (42.6)	

Table 3. ROC analysis and logistic regression of NT₅₀ magnitude as a predictor for developing a subsequent symptomatic disease, stratified by infection history.

	AUC ^a	CI 95 ^b	Threshold (NT ₅₀)	Sensitivity	Specificity	OR ^c	CI 95
Combined							
Part.Mature ^d Vero	0.64	0.54 to 0.74	898.13	0.94	0.08	0.86	0.75 to 0.96
Mature Vero	0.62	0.52 to 0.72	475.83	0.9	0.32	0.82	0.70 to 0.94
Part.Mature ^d Vero DC-SIGN	0.65	0.55 to 0.75	701.95	0.9	0.14	0.85	0.73 to 0.96
Mature Vero DC-SIGN	0.64	0.54 to 0.74	180.25	0.9	0.29	0.72	0.53 to 0.92
Primary							
Part.Mature ^d Vero	0.68	0.56 to 0.81	392.70	0.9	0.29	0.75	0.58 to 0.93
Mature Vero	0.63	0.49 to 0.76	367.95	0.9	0.26	0.79	0.63 to 0.97
Part.Mature ^d Vero DC-SIGN	0.68	0.56 to 0.81	276.60	0.9	0.32	0.73	0.55 to 0.92
Mature Vero DC-SIGN	0.70	0.58 to 0.82	96.81	0.93	0.35	0.31	0.12 to 0.65
Secondary							
Part.Mature ^d Vero	0.54	0.37 to 0.71	981.84	1	0.10	<i>ns</i>	-
Mature Vero	0.59	0.43 to 0.75	767.76	1	0.17	<i>ns</i>	-
Part.Mature ^d Vero DC-SIGN	0.56	0.39 to 0.73	891.09	0.95	0.10	<i>ns</i>	-
Mature Vero DC-SIGN	0.54	0.38 to 0.70	455.15	0.91	0.21	<i>ns</i>	-

^aAUC = Area under the curve, ^bCI95 = 95% Confidence interval, ^cOR = Odds ratio, ^dPart. Mature = Partially mature virion.